Currently, GenAns Biotech is conducting investigator-initiated trials for several gene therapies, including GA001 for ...

CGT Global, a leading biotechnology company driving the development and delivery of innovative cell and gene therapies, today ...

The FDA's approval of the first CRISPR-Cas9–based gene therapy marked a major milestone in biomedicine, validating genome ...

Sarepta did not hold an investor call for its second-quarter earnings report or provide an updated full-year revenue outlook.

A 26-year-old Downriver man seen at Children’s Hospital of Michigan in Detroit since infancy for a rare bleeding disorder in ...

Sarepta Therapeutics (SRPT) stock in focus as report says company hired a Trump-linked lobbying firm after deaths linked to ...

Enrollment Complete in Cohorts 1 and 2 of MyPEAK™-1 Phase 1b/2 Trial of TN-201 for MYBPC3-associated HCM; Positive DSMB ...

Discover insights from MaxCyte's Q2 2025 earnings call, including revised revenue guidance, headwinds impact, and strategies for growth in the cell ...

Cash runway extended into 2028; expected to enable multiple meaningful clinical data read-outs -- APOE program added to ...

Novo Nordisk will advance its acquired ATTR amyloidosis with cardiomyopathy monoclonal antibody (mAb) to Phase III trials.

In this week’s edition of InnovationRx, we look at a biotech entrepreneur treating a rare genetic disease, new tech aimed at ...

Q2 2025 Earnings Call Transcript August 6, 2025 Charles River Laboratories International, Inc. misses on earnings ...